BB0744 Affects Tissue Tropism and Spatial Distribution of Borrelia burgdorferi by Wager, Beau et al.
BB0744 Affects Tissue Tropism and Spatial Distribution of Borrelia
burgdorferi
Beau Wager,a Dana K. Shaw,a* Ashley M. Groshong,b* Jon S. Blevins,b Jon T. Skarea
Department of Microbial Pathogenesis and Immunology, College of Medicine, Texas A&M Health Science Center, Bryan, Texas, USAa; Department of Microbiology and
Immunology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USAb
Borrelia burgdorferi, the etiologic agent of Lyme disease, produces a variety of proteins that promote survival and colonization
in both the Ixodes species vector and various mammalian hosts. We initially identified BB0744 (also known as p83/100) by
screening for B. burgdorferi strain B31 proteins that bind to 11 integrin and hypothesized that, given the presence of a signal
peptide, BB0744 may be a surface-exposed protein. In contrast to this expectation, localization studies suggested that BB0744
resides in the periplasm. Despite its subsurface location, we were interested in testing whether BB0744 is required for borrelial
pathogenesis. To this end, a bb0744 deletion was isolated in a B. burgdorferi strain B31 infectious background, complemented,
and queried for the role of BB0744 following experimental infection. A combination of bioluminescent imaging, cultivation of
infected tissues, and quantitative PCR (qPCR) demonstrated thatbb0744mutant B. burgdorferi bacteria were attenuated in the
ability to colonize heart tissue, as well as skin locations distal to the site of infection. Furthermore, qPCR indicated a significantly
reduced spirochetal load in distal skin and joint tissue infected withbb0744mutant B. burgdorferi. Complementation with
bb0744 restored infectivity, indicating that the defect seen inbb0744mutant B. burgdorferiwas due to the loss of BB0744.
Taken together, these results suggest that BB0744 is necessary for tissue tropism, particularly in heart tissue, alters the ability of
B. burgdorferi to disseminate efficiently, or both. Additional studies are warranted to address the mechanism employed by
BB0744 that alters the pathogenic potential of B. burgdorferi.
In 2013, the CDC estimated that the number of Americans diag-nosed with Lyme disease was300,000 per year, indicating that
infection with Borrelia burgdorferi represents a significant public
health concern in theUnited States, particularly in areas where the
disease is endemic (1, 2). The etiologic agent of Lyme disease, B.
burgdorferi, is an extracellular pathogenic spirochetal bacterium
that has adapted to invade and colonize various organs within
mammalian hosts following transmission by an infected Ixodes sp.
tick (3–6). Although a skin rash and influenza-like symptoms are
typical symptoms of early Lyme disease, untreated patients can
present with lymphocytomas, myocarditis, meningitis, arthritis,
and a large variety of other debilitating inflammatory symptoms
(7–12). Themechanisms underlying the dissemination of B. burg-
dorferi to the various organs it colonizes during infection have yet
to be discerned.
Some factors that may influence the severity and type of symp-
toms seen in Lyme disease patients can be inferred from the results
of mouse model studies and include the location of the initial
infection, the immune response of the host, and the amount of
spirochetes able to disseminate and colonize affected organs (13–
19). The ability of B. burgdorferi to evade the immune response
and colonize tissues lies within the numerous lipoproteins that
adorn its outer surface (20). Many of these lipoproteins have been
characterized as ECM (extracellular matrix) adhesins, including
those that bind to decorin (DbpA), fibronectin (BBK32), glycos-
aminoglycans (Bgp; BBK32; DbpA), and integrins (BBB07, P66),
as well as many others with unknown host ligands (21–27). B.
burgdorferi also expresses on its surface a variable surface antigen,
VlsE, and five different factorH binding proteins designated com-
plement regulator-acquiring surface proteins, which are involved
in the evasion of complement-dependent killing (28, 29).
A study byMotameni et al. showed a correlation betweenmyo-
carditis and arthritis severity and the location of the B. burgdorferi
injection (16). The results imply that the available route of dissem-
ination of the spirochetes has an impact on the extent of infection.
Previously, studies have focused primarily on the route of dissem-
ination through either connective tissues or the bloodstream (13,
30–35). BBK32 has been implicated as one of the proteins in-
volved in blood vessel dissemination, and spirochetes have been
visualized adhering to and transmigrating across blood vessel ep-
ithelial cell layers during infection (36). However, there is increas-
ing evidence thatB. burgdorferimay alsomigrate through the lym-
phatic system (16, 23, 37).
Lymph nodes are rapidly and consistently colonized by B.
burgdorferi in both early and late stages of infection (37, 38). The
time in which lymph nodes, joints, and other connective tissues
become infected is relative to their proximity to the inoculation
site (31, 37). B. burgdorferi may travel through the lymphatic sys-
tem not only for dissemination but also to interfere with the im-
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mune response and gain a survival advantage for spirochetes in-
fecting all tissues (39). Recent studies have also found that, in
contrast to BBK32, DbpA is involved in transmission via the lym-
phatic system, indicating that distinctmodalitiesmay be operative
in borrelial dissemination (23, 32, 33, 36). It is probable that B.
burgdorferi has adapted to multiple routes of dissemination, as
quick systemic infection is an important function for a pathogen
that travels from host to host by tick bite at random locations.
This study focused on the protein p83/100, which is encoded
by the chromosomal gene bb0744. The impact and role of BB0744
during infection have not been previously studied, but it is a
known serodiagnostic antigen for Lyme infection (40–42).
BB0744 has also been observed forming complexes with other
proteins isolated in outer membrane vesicles, suggesting an asso-
ciation with the outer membrane envelope (43). In this study, we
show that BB0744 is required for optimal tissue tropism and/or
normal dissemination in mice infected by needle inoculation
given thatB. burgdorferi strains lacking this gene exhibit a defect in
colonization to both distal skin sites and the heart and exhibit
reduced bacterial loads in lymph node and joint tissues.
MATERIALS AND METHODS
Bacterial strains. All of the strains used in this study are listed in Table 1.
Escherichia coliMach1-T1R cells were utilized for cloning, and C41(DE3)
cells (Lucigen, Middleton, WI) were used for expression of recombinant
BB0744. E. coli strains were grown at 37°Cwith aeration in lysogeny broth
(LB). Strains were maintained under antibiotic selection with gentamicin
at 5 g/ml, spectinomycin at 100 g/ml, kanamycin at 50 g/ml, chlor-
amphenicol at 25g/ml, ampicillin at 100g/ml, and carbenicillin at 100
g/ml.
B. burgdorferi strains were grown in BSK-II medium supplemented
with 6% normal rabbit serum (Pel-Freez, Rogers, AR) lacking gelatin at
32°C with 1% CO2 (44). Borrelial strains were maintained with antibiotic
selection with kanamycin at 300 g/ml, streptomycin at 50 g/ml, or
gentamicin at 50 g/ml. The use of infectious B. burgdorferi in this study
was reviewed and approved by the Institutional Biosafety Committee at
Texas A&M University.
Plasmid constructs.All of the plasmids utilized in this study are listed
in Table 1. All DNA fragments were amplified by PCR with TaKaRa
PrimeSTARGXLDNApolymerase. Plasmid p744KOwas constructed via
the Gibson assembly method (45). A streptomycin resistance cassette
(PflgB-aadA; Str
r) was amplified fromplasmid pKFSS1 (46). A fragment of
pCR2.1-TOPO (Invitrogen) was amplified for use as the vector backbone.
The 1.5-kb DNA fragments immediately upstream and downstream of
bb0744 were both amplified from a ML23 genomic DNA sample. The
primers were designed such that the 5= end of the bb0744 upstream frag-
ment contained a 20-bp overlap at the 3= end of the pCR2.1 fragment and
its 3= end contained a 20-bp overlap at the 5= end of the Strr cassette. The
primers for the bb0744 downstream fragment were similarly designed to
overlap the 5= end of the pCR2.1 fragment and the 3= end of the Strr
cassette. The bb0744 upstream fragment, bb0744 downstream fragment,
and Strr cassette were combined with Gibson assembly master mix (New
England BioLabs) into one product and amplified by PCR. This fragment
TABLE 1 Plasmids and bacterial strains used in this study
Strain or plasmid Description or genotype Source or reference
Plasmids
pCR2.1-TOPO Kanr Carbr Invitrogen
pKFSS1 Specr in E. coli, Strr in B. burgdorferi; borrelial shuttle vector 46
p744KO Kanr Carbr Specr/Strr; 1.5-kb regions up- and downstream of bb0744 flanking a Specr/Strr cassette
ligated into pCR2.1-TOPO
This study
pCR-Blunt II-TOPO Kanr Invitrogen
p744Comp Kanr Gentr; 1.5-kb regions up- and downstream of bb0744 flanking bb0744 and a Gentr cassette ligated
into pCR-Blunt II-TOPO
This study
pBSV2G Gentr; borrelial shuttle vector 47
pBBE22luc Kanr, plasmid containing bbe22 and B. burgdorferi codon-optimized firefly luc gene under control of
strong borrelial promoter (PflaB-luc)
31
pCR2.1-recA Kanr; recA gene in pCR2.1-TOPO 67
pCR2.1--actin Kanr; Actb gene in pCR2.1-TOPO 68
pGEM-T Easy Ampr; TA cloning vector Promega
pProEX-HTb Ampr; recombinant expression construct with N-terminal, TEVa protease-cleavable His6 tag Life Technologies
pRARE Camr; plasmid expressing six rare tRNAs to improve expression of genes containing rare E. coli codons EMDMillipore
pProEX::BB0744 Ampr; pProEX-HTb containing bb0744; construct lacks first 22 amino acids of BB0744 This study
B. burgdorferi strains
ML23 B. burgdorferi strain B31 clonal isolate missing lp25 55
ML23/pBBE22luc Kanr 31
SH100 ML23 bb0744::Strr This study
SH200 ML23 bb0744-Gentr; Strs This study
SH100 pBBE22luc ML23 bb0744::Strr containing pBBE22luc; Strr Kanr This study
SH200 pBBE22luc ML23 bb0744-Gentr; Strs containing pBBE22luc; Gentr Kanr This study
5A4 Clonal isolate of strain B31 containing all plasmids 69
5A4NP1 5A4 bbe02::Kanr 70
297 Clinical isolate 71
E. coli strains
Mach1-T1R F 80 lacZM15 lacX74 hsdR (rK
mK
) recA1398 endA1 tonA Invitrogen
C41(DE3) F ompT hsdSB (rB
mB
) gal dcm(DE3) Lucigen
a TEV, tobacco etch virus.
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was ligated into the pCR2.1 backbone to create complete plasmid
p744KO, which was chemically transformed into Mach1-T1R.
For cis complementation of bb0744, plasmid p744Comp was con-
structed. Specifically, DNA fragments containing the 1.5-kb sequence up-
stream of bb0744 and bb0744 itself and a 1.5-kb sequence downstream of
bb0744 were amplified from B. burgdorferi genomic DNA. A gentamicin
resistance cassette (PflgB-aacC) was amplified from plasmid pBSV2G (47).
These three fragments were amplified with 20-bp overlapping pieces and
annealed to each other by themethod of overlap extension PCR (48). This
product was ligated into pCRBlunt II-TOPO and chemically transformed
into Mach1-T1R.
The bb0744 open reading frame (ORF) of B. burgdorferi strain 297 was
amplified with primers 5= BB0744 ORF and 3= BB0744 ORF (Integrated
DNA Technologies, Coralville, IA) with genomic DNA as the template.
The primers incorporated BamHI and NotI restriction sites at the 5= and
3= ends, respectively. The 5= primer was also designed to omit the N-ter-
minal 22 amino acids of the ORF, which was predicted to contain a signal
peptide by SignalP 4.1. The amplicon was TA cloned into pGEM-T Easy
(Promega Corp., Madison, WI) and confirmed by sequencing. The con-
struct was excised with BamHI and NotI and ligated into the pProEX-
HTb expression vector (Life Technologies) digested with the same en-
zymes to generate pProEX::BB0744.
Expression and purification of recombinant BB0744. To produce
recombinant BB0744, C41(DE3) was transformed with pProEX::BB0744
and pRARE (EMDMillipore, Billerica, MA). Cultures were induced for 3
hwith 1mM isopropyl--D-thiogalactopyranoside (IPTG). Recombinant
BB0744, which includes an N-terminal His6 tag, was affinity purified with
HisPurNi-nitrilotriacetic acid (NTA) resin (Thermo Scientific, Rockford,
IL) under native conditions in accordance with the manufacturer’s pro-
tocol. Fractions containing recombinant BB0744 were then buffer ex-
changed into 20 mM Tris-HCl (pH 8)—350 mMNaCl and concentrated
with an AmiconUltra-15 centrifugal filtration unit (EMDMillipore) with
a 50-kDa molecular mass cutoff. Recombinant BB0744 was resolved on a
HiPrep 16/60 Sephacryl S-300 HR gel filtration column with an Äkta
UPC-10 fast-performance liquid chromatography (FPLC) system (GE
Healthcare Biosciences, Piscataway, NJ). The protein was eluted with 20
mM Tris-HCl (pH 8)–350 mM NaCl, and samples of the fractions were
analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) to assess the yield. Fractions containing recombinant
BB0744 were pooled, buffer exchanged into 20mMTris-HCl (pH 8), and
concentrated as described above. Concentrated proteins were purified
further by FPLC and MonoQ 5/50 GL anion-exchange column chroma-
tography (GE Healthcare Biosciences). Recombinant BB0744 that bound
to the MonoQ column was eluted with a linear gradient up to 1 M NaCl
buffered in 20 mM Tris-HCl (pH 8). On the basis of SDS-PAGE, recom-
binant BB0744 was purified to apparent homogeneity (i.e.,	95%).
Generation of polyclonal antisera. BB0744-specific polyclonal anti-
serum was generated in 3- to 4-week-old female Sprague-Dawley rats
(Harlan, Indianapolis, IN) as described byGroshong et al. (49). Briefly, 25
g of recombinant BB0744 protein was combined with complete
Freund’s adjuvant (Sigma, St. Louis, MO). Rats were injected intraperito-
neally with the emulsified antigen-adjuvant mixture and then boosted
twice with 25 g of recombinant BB0744 protein emulsified with incom-
plete Freund’s adjuvant (Sigma). Serawere collected 2weeks after the final
boost. TheUniversity of Arkansas forMedical Sciences (UAMS) is accred-
ited by the International Association for Assessment and Accreditation of
Laboratory Animal Care (AAALAC), and all immunization protocols
were approved by theUAMS Institutional Animal Care andUse Commit-
tee (IACUC).
Membrane protein phase partitioning. Membrane protein phase
partitioning was performed as previously described (49). B. burgdorferi
cells were collected at the mid-log growth phase and washed with phos-
phate-buffered saline (PBS). Cells were then sonicated and incubated
overnight in 2%TritonX-114 at 4°C. Samples were centrifuged to remove
insoluble material and then phase partitioned by warming to 37°C. The
detergent and aqueous phases were separated and washed, and protein
was precipitated in cold acetone. Precipitated protein was prepared in
SDS-PAGE buffer and analyzed by Western blotting. OspA was included
as a positive control for membrane localization (colorimetric detection),
and BB0796 was used as a positive control for aqueous localization
(chemiluminescent detection) (20). BB0744 was detected by colorimetric
assay.
IFAs for surface accessibility. Immunofluorescence assays (IFAs)
were performed as described by Groshong et al. (49). Briefly, B. burgdor-
feri cells were grown to mid-log growth phase and harvested by centrifu-
gation. For permeabilized samples, spirochetes were washed with
PBS-MgCl2 and immediately applied to silylated slides. The cells were
allowed to air dry and then fixed by heating to 65°C for 1 h and incubation
in acetone. The samples were then blocked for 1 h and incubation with
primary antibodies (anti-OspA monoclonal, chicken anti-FlaB, and rat
anti-BB0744 antibodies) for 1 h. For nonpermeabilized samples, spiro-
chetes were washed and incubated in solutionwith primary antibodies for
1 h. Samples were then applied to silylated slides and fixed with 4% form-
aldehyde. The slides were then incubated with fluorescent-dye-conju-
gated secondary antibodies (anti-mouse antibody conjugated with Alexa
594, anti-chicken antibody conjugated with Alexa 647, and anti-rat anti-
body conjugated with Alexa 448; Life Technologies) and fixed again with
formaldehyde. Cells were visualized with a Nikon Ti-Umicroscope and a
60
 oil immersion objective, and imaging was performed with a D5-
QilMc digital camera (Nikon, Melville, NY).
Proteinase K accessibility assay. Proteinase K assays were performed
as previously described (49). B. burgdorferi cells were pelleted following
growth to mid-log phase and washed with PBS. The samples were then
divided. Samples were either mock treated with PBS or treated with pro-
teinase K (50, 51). Proteinase K accessibility assays were also performed in
the presence or absence of 0.05% Triton X-100 (Promega). Phenylmeth-
anesulfonyl fluoride was used to stop digestion after 1 h, and the samples
were placed in SDS-PAGE buffer, separated by SDS-PAGE, and analyzed
by Western blotting. FlaB was used as a negative (periplasmic) control,
and OspA was used as a positive (outer surface) control.
SDS-PAGE and immunoblot analysis. B. burgdorferi protein lysates
were resolved by SDS-PAGE, and gels were either stained with Coomassie
brilliant blue R-250 (Sigma-Aldrich, St. Louis, MO, USA) or transferred
to polyvinylidene difluoride membranes and immunoblotted. Primary
antibodies were used at the following dilutions: rat anti-BB0744 at
1:5,000, chicken anti-FlaB IgY at 1:25,000, rat anti-OspA at 1:25, mouse
anti-OspC at 1:1,000, and rat anti-BB0796 at 1:1,500 (49). Appropriate
horseradish peroxidase (HRP)-conjugated secondary antibodies (anti-
mouse IgG-HRP, anti-rat IgG-HRP [Invitrogen, Carlsbad, CA], and don-
key anti-chicken IgY antibodies at 1:2,500) were used to detect immune
complexes. The membranes were washed extensively in PBS with 0.2%
Tween 20 and developed with the Western Lightning Chemiluminescent
Reagent plus system (PerkinElmer, Waltham, MA, USA) for chemilumi-
nescent detection or with 4-chloro-1-naphthol as the substrate for color-
imetric detection.
Transformation of B. burgdorferi. B. burgdorferi strain ML23 was
made competent and transformed by electroporation (52, 53). For the
bb0744 deletion and subsequent cis complementation, linearized versions
of p744KO and p744Comp (Table 1), respectively, were used for electro-
poration. All transformants were selected forwith appropriate antibiotics.
The resulting bb0744 deletion mutant was designated SH100, and its cor-
responding cis complement was termed SH200. These strains were addi-
tionally screened for the presence or absence of bb0744 by PCR product
size and DNA sequencing as previously described (54). Once validated,
strains SH100 and SH200 were transformed with pBBE22luc under kana-
mycin selection and transformants were screened by PCR for the presence
of the shuttle vector (31). Strains were then evaluated for plasmid content,
and only those that maintained the complete plasmid set of the parent
strain were used. SH200 was tested for sensitivity to streptomycin to rule
out a mixed population.
BB0744 Is Required for Tissue Tropism
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In vitro bioluminescence assays. ML23/pBBE22luc, SH100/
pBBE22luc, and SH200/pBBE22lucwere grown tomid-log phase and con-
centrated to 108 cells/ml in duplicate in a 96-well plate. Each sample was
treated with a final concentration of 667 M D-luciferin (Research Prod-
ucts International Corp., Mt. Prospect, IL) in PBS and immediately mea-
sured for luminescence in a FluorChem E Digital Darkroom (Protein-
Simple).
Infectivity studies. All animal experiments were performed in accor-
dance with AAALAC guidelines. The Texas A&M University IACUC
granted approval for all mouse infections conducted. Four- to 6-week-old
female BALB/c mice were used to enhance the signal for bioluminescence
imaging. Themice were infected intradermally within the abdominal skin
with an inoculum of either 103 or 105 cells of B. burgdorferi strain ML23/
pBBE22luc, SH100/pBBE22luc, or SH200/pBBE22luc. Themicewere then
imaged as described below. Twenty-one days postinfection, themice were
sacrificed and pinna, abdominal skin, inguinal lymph node, heart, spleen,
bladder, and tibiotarsal joint tissues were aseptically removed and placed
directly into BSK-II medium with appropriate antibiotics. Qualitative
analysis of infection was performed by incubating these tissue-inoculated
cultures at 32°C and 1% CO2 for 3 weeks. The presence of B. burgdorferi
was scored by dark-field microscopy (55).
In vivo bioluminescent imaging. To detect luciferase activity, mice
were intraperitoneally injected with D-luciferin prior to imaging with an
IVIS Spectrum live-animal imaging system (Caliper Life Sciences, Hop-
kinton, MA) (31), with the exception of one mouse that did not receive
D-luciferin and served as a negative control for background luminescence.
Mice were imaged at 1 h and 1, 4, 7, 10, 14, and 21 days after B. burgdorferi
infection by methods described previously (31). Luminescence was mea-
sured with 1- and 10-min exposures to obtain images for quantification
and visual representation, respectively. Regions of interest (ROI) were
selected to measure luminescence in photons per second from the 1-min
exposure images by using an equal area of the whole body for all of the
mice in all of the experiments. The luminescence for mice that received
D-luciferin was averaged and normalized by subtracting the background
luminescence on the negative-controlmouse. All images from the 10-min
exposures were corrected for the background and set on a color scale with
7.5 
 103 and 1 
 105 photons per second as the minimum and maxi-
mum, respectively.
Quantitative PCR (qPCR). Quantitative analysis of pinna, inocula-
tion site skin (abdominal skin), inguinal lymph node, and tibiotarsal joint
tissues from infected mice was performed by extracting DNA with the
Roche High Pure PCR Template preparation kit as described previously
(38). B. burgdorferi genome copies were enumerated along with mamma-
lian genome copies with iTaq Universal SYBRGreen Supermix (Bio-Rad)
and the Applied Biosystems 7900HT Fast real-time PCR system. Approx-
imately 100 ng of total DNAwas used in each reactionmixture with either
a primer set for the amplification of theB. burgdorferi recA gene (38, 56) or
a primer set for amplification of the Mus musculus -actin gene (57).
Borrelial and mammalian genomic copy numbers were determined for
each sample by normalizing the threshold cycle (CT) values of individual
tissues to a standard curve established with 10 to 105 copies of pCR2.1-
recA and pCR2.1--actin (Table 1). All samples were assayed in triplicate,
and the standard curve for each plate had a linear regression coefficient of
determination (R2) of0.98.
Statistical analysis. To determine significant differences between
samples in the real-time qPCR analysis, a one-way analysis of variance
(ANOVA) of the strains in each tissue type was performed with a Tukey
multiple-comparison test. For the bioluminescence signal data, two-way
ANOVAs were performed with Bonferroni posttests. Statistical signifi-
cance was accepted when the P values were0.05 for all of the statistical
analyses employed.
RESULTS
BB0744 is located subsurface in the cell envelope. Screening for
11 integrin binding proteins by a Western overlay approach
coupled with mass spectroscopy identified BB0744 as a potential
adhesin to thesemammalian host structures. This binding is likely
due to an RGD integrin binding motif at residues 146 to 148 (not
shown; 21). BB0744 is a 700-residue protein with a predicted mo-
lecular mass of 81 kDa and has historically been referred to as
p83/100 (58). In addition, BB0744 is a well-established antigen
that is used to diagnose human Lyme borreliosis (40–42). The
deduced amino acid sequence of BB0744 predicts an amino-ter-
minal signal peptide that would be subject to cleavage by leader
peptidase I. However, the sequence lacks evidence of predicted
transmembrane segments that could be used to integrate the pro-
tein into a membrane bilayer. Nevertheless, the presence of an
amino-terminal signal sequence, coupled with the atypical cell
envelope properties of B. burgdorferi, suggested that BB0744
might be an outer membrane protein. Additional support of sur-
face localization of BB0744 comes from its presence in outer
membrane vesicle preparations from B. burgdorferi (not shown)
and a prior study showing that BB0744 (referred to as p83/100)
was associated with membrane-associated proteins (59, 60), as
well as those proteins that were deemed soluble (60). Given these
linkages to the borrelial cell envelope and the putative integrin-
bindingmotif, we addressed the location of BB0744 in B. burgdor-
feri by three independent methods.
First, whole-cell extracts of B. burgdorferi strain B31 derivative
5A4 were partitioned into aqueous and detergent phase proteins
with the detergent Triton X-114. BB0744 was present in the aque-
ous phase along with control soluble protein BB0796 (20) and
absent from the detergent phase, whereas the cell surface lipopro-
tein OspA associated with the detergent phase as expected
(Fig. 1A).
Second, the whole-cell extracts of B. burgdorferi were collected
from cells treated with PBS or proteinase K. Proteins on the outer
surface of the bacteria were cleaved by proteinase K, while those in
the periplasm or cytoplasm would be protected. The presence of
the surface-exposed OspC lipoprotein, the subsurface endoflagel-
lar structural protein FlaB, and BB0744 was detected by Western
blotting of both samples. The amount of OspC was reduced be-
cause of cleavage by proteinase K, while both periplasmic FlaB and
BB0744 remained unaltered (Fig. 1B). As a control, Triton X-100
was added to samples and treated with proteinase K to ensure that
these proteins were not insensitive to proteolysis (Fig. 1B). The
protection of BB0744 from proteinase K was not affected by alter-
ing the temperature, carbon dioxide, or pH of the culture condi-
tions (data not shown). In addition, no other culture condition,
including those that induce high levels of mammalian specific
antigens (notably, OspC and DbpA) resulted in a change in
BB0744 expression (not shown).
Lastly, borrelial cells were either permeabilized by heat fixation
or left untreated prior to incubation with antibodies against sur-
face-exposed OspA, subsurface FlaB, or BB0744. Appropriate flu-
orescent-dye-conjugated secondary antibodies showed that OspA
was fluorescently labeled on both permeabilized and nonperme-
abilized cells, whereas BB0744 was detected only in permeabilized
cells, similar to FlaB, a borrelial protein that is known to be
periplasmically localized (Fig. 2). Taken together, these results
suggest that BB0744 is not present on the cell surface of B. burg-
dorferi under any of the in vitro conditions tested.
Construction of bb0744 mutant and complemented
strains. Despite the subsurface localization of BB0744, its pres-
ence within the cell envelope prompted us to determine whether
Wager et al.
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BB0744 played a role in borrelial pathogenesis. To this end,
bb0744was deleted from the chromosome by homologous recom-
bination and replaced with a streptomycin resistance (Strr) cas-
sette in B. burgdorferi strain ML23 (55, 61) (Fig. 3A). Resulting
transformants were screened by PCR for evidence of the bb0744
deletion (bb0744::Strr) with oligonucleotide primers (listed in
Table 2) that amplify a 5.1-kb fragment in the parent strain and a
4.3-kb fragment in the resulting bb0744::Strr strain (Fig. 3B).
Each bb0744::Strr strain obtained was then screened for its total
borrelial plasmid profile.Only those strains that retained the com-
plete plasmid profile were utilized. Western immunoblot analysis
with amonospecific polyclonal antibody to BB0744 demonstrated
that BB0744 was not produced in putative deletion strain SH100
(Fig. 3C and D).
All attempts to complement bb0744 in transwere unsuccessful.
Therefore, we complemented bb0744 in cis by integrating bb0744
and a linked gentamicin resistance cassette into ML23 bb0744::
Strr (Fig. 3A). Transformants were screened for gentamicin resis-
tance (Genr) and streptomycin sensitivity. Isolates that replace the
bb0744::Strr allele with intact bb0744 linked to the Genr marker
exhibit a 6.1-kb amplified product following PCR analysis with
primers P1 and P2 (Fig. 3A and B). The resulting strain was
designated SH200. Western immunoblot analysis showed that
the complemented strain expressed BB0744 protein (Fig. 3D).
The ML23 bb0744 knockout (SH100) and complemented
strain (SH200) were then transformed with the shuttle vector
pBBE22luc. The presence of the bbe22 and bbe23 genes on
pBBE22luc complements lp25-deficient ML23 and restores infec-
tivity (62). Plasmid pBBE22luc also contains the borrelial codon-
optimized firefly luciferase gene, luc, (63) to enable biolumines-
cent tracking of the spirochetes (31, 54).
There was no statistically significant difference among the
growth rates ofML23/pBBE22luc, SH100/pBBE22luc, and SH200/
pBBE22luc, indicating that the expression of bb0744 is not impor-
tant for in vitro growth or replication (not shown). No overt mor-
phological alterations were observed. Lastly, a qualitative test for
the expression of luciferase by each strain was performed that
verified comparable levels of luminescence in all of the strains
tested (data not shown).
Assessment of the bb0744 deletion in theML23 background.
In previous studies, bioluminescent imaging served as a powerful
tool to determine the role of specific gene products in the coloni-
zation and dissemination of B. burgdorferi (31, 54). To assess the
role of BB0744 in borrelial pathogenesis in a temporal and spatial
manner, BALB/c mice were infected intradermally with a low
(103) or high (105) dose of ML23/pBBE22luc, SH100/pBBE22luc,
or SH200/pBBE22luc. Low-level luminescence was detected dur-
FIG 1 Determination of the cell envelope localization of BB0744. (A) BB0744 is a soluble protein. B. burgdorferi 5A4 cells were partitioned into detergent (DET)
and aqueous (AQ) phases with Triton X-114. Precipitated protein samples were resolved by SDS-PAGE and analyzed by Western blotting. OspA was included
as a positive control for a membrane-localized protein (DET lane), and BB0796 was used as a positive control as an aqueous-phase protein (AQ lane). BB0744
was detected only in the aqueous phase. (B) BB0744 is not protease accessible in intact borrelial cells. B. burgdorferi 5A4 cells were suspended in PBS alone (Intact
lanes) or PBS containing Triton X-100 (Triton X-100 lanes). Minus and plus signs signify the presence of added proteinase K (PK). The resulting B. burgdorferi
samples were resolved by SDS-PAGE and analyzed by Western blotting. FlaB and OspC were used as controls for subsurface and surface-exposed proteins,
respectively. No decrease in BB0744 was observed after proteinase K treatment. Lanes MW contained prestained protein molecular size markers (sizes are in
kilodaltons).
FIG 2 Surface exposure of BB0744.B. burgdorferi 5A4 cells were either washed
or permeabilized by heat fixation prior to incubation with antibodies to the
proteins listed on the right. Nonpermeabilized cells were then fixed to silylated
slides with formaldehyde, and all cells were incubated with appropriate fluo-
rescent secondary antibodies (anti-mouse Alexa 594 for mouse antibody to
OspA, anti-chicken Alexa 647 for chicken antibody to FlaB, and anti-rat Alexa
488 for rat antibody to BB0744). FlaB served as a periplasmic protein control,
and OspA was used as an outer surface protein control. BB0744 was labeled
only in permeabilized cells. Scale bars, 10 m.
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ing the exposures of mice infected with the high dose at the 1-h
postinfection time point for all of the strains tested, indicating that
all of themice were infected.When looking at total body lumines-
cence, mice infected with either dose ofML23/pBBE22luc showed
a luminescence peak corresponding to the highest concentration
of live B. burgdorferi at day 7, with a secondary peak at day 14, as
previously observed (31). Surprisingly, mice infected with the
low dose of SH200/pBBE22luc showed a much higher peak at
day 7 and mice infected with the high dose had a luminescence
peak as early as day 4. However, both bb0744-expressing strains
have prominent luminescence peaks. Comparatively, SH100/
pBBE22luc-infected mice had low levels of luminescence with a
minor peak appearing only on day 14 (Fig. 4; see Fig. S1 in the
supplemental material).
When the imaging data are analyzed, a clear difference between
the patterns of infection with ML23/pBBE22luc and SH100/
pBBE22luc emerges. In the mice infected with the high dose, on
day 4 for SH200/pBBE22luc and day 7 for ML23/pBBE22luc, a
high level of fluorescence is observed on the abdomens of themice
radiating from the site of B. burgdorferi injection. On day 10 for
both strains, the luminescence is decreased because of partial
clearing of spirochetes by virtue of the burgeoning humoral re-
sponse to B. burgdorferi (13, 61, 64). On day 14, the signal returns
but is now distributed more widely across the entire torso and
extends to the limbs and head. On day 21, while the signal is
reduced again, it is alsomore concentrated in the head, limbs, and
lower abdomen (Fig. 4B). In contrast, throughout the SH100/
pBBE22luc infection cycle, the luminescence signal only leaves the
confines of the lower abdomen to spread to the lower limbs. A
high signal level is never observed on the upper torso or head of
mice infected with either dose of SH100/pBBE22luc. This pattern
of infection suggests that the bb0744 knockout was not attenuated
in its ability to infect and subsist in mice but rather exhibits a
dissemination defect in moving away from the initial site of infec-
tion.
At day 21, all infected mice were sacrificed and their tissues
were processed for cultivation and qPCR. Cultivation of tissues
from mice infected with 103 cells of parental infectious strain
ML23/pBBE22luc or SH200/pBBE22luc demonstrated infection
of all tissues (Table 3). While SH100/pBBE22luc was capable of
colonizing the joint, bladder, lymph node, and skin near the site of
infection independently of the dose, no spirochetes were observed
FIG 3 Construction of bb0744 knockout and complemented strains. (A) Construction of the bb0744::Strr mutant strain and cis complementation strategies.
Representation of the bb0744 locus in theB. burgdorferiB31 strainML23 (parent) chromosome and subsequent replacement of intact bb0744with a streptomycin
resistance (Strr) cassette (PflgB-aadA) by homologous recombination with linearized p744KO, resulting in strain SH100 (bb0744). For complementation, the
Strr cassette of the bb0744 knockout mutant is replaced with an intact copy of bb0744 linked to a gentamicin resistance cassette (PflgB-aacC) to yield strain SH200
(bb0744 Comp). Lines with arrows depict the locations of primers P1 and P2 (Table 2), which were used to confirm the deletion mutation and subsequent
complemented (Comp) strain. Note that the gene depictions shown are not to scale. (B) Confirmation of thebb0744::Strr strain and cis-complemented strains.
The configuration of the bb0744 locus was determined by PCR for theML23/pBBE22luc, SH100/pBBE22luc, and SH200 strains with the oligonucleotide primers
depicted in panel A. The values to the left are DNA size markers (sizes are in kilobases). (C, D). The bb0744::Strr strain does not produce BB0744 protein. B.
burgdorferi whole-cell lysates were separated by SDS-PAGE, immunoblotted, and probed with antisera to BB0744. The Coomassie-stained gel used as a loading
control is shown in panel C. The presence of BB0744 was detected with antiserum specific for BB0744 in panel D.
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in the cultures of heart, spleen, or ear tissue of any mice infected
with either the low or the high dose (Table 3). One possible expla-
nation for this inability to spread may be impaired motility. To
address this possibility, the bb0744::Strr mutant was compared
to its parent strain by usingmotility agarose. No significant differ-
ence in motility or swarming was evident (not shown), suggesting
that the defect in colonization was not due to compromised loco-
motion of the bb0744 mutant.
qPCR was also performed with total DNA extracted from
mouse ear pinna, abdominal skin, lymph node, and tibiotarsal
joint and was normalized to mouse tissue as previously described
(31, 38) (Fig. 5). No significant difference in borrelial genome
copy numbers between any strains within the abdominal skin was
observed. However, there were significant differences in the ear
pinna, lymph node, and joint tissues between the bb0744::Strr
mutant and its parent or complemented derivatives. In particular,
and consistent with the cultivation data, the qPCR detected no
genomic copies of SH100/pBBE22luc in the ear pinna tissue
(Fig. 5). Taken together, these data suggest that BB0744 is needed
for optimal tissue tropism and/or dissemination during experi-
mental infection by B. burgdorferi, given that significantly lower
numbers of spirochetes are observed in joint tissue and distal skin
sites, respectively.
DISCUSSION
The ability to adhere to the surface of host cells is an essential step
in the colonization process for all pathogenic bacteria. As a part of
its life cycle, B. burgdorferi is transmitted between the tick vector
and mammalian host and disseminates to various tissues during
the infection process. Tissues contain diversity within their ECM,
with various subunits and ratios of collagens, fibronectin, integ-
rins, fibrinogen, and laminin (65). ECM-binding adhesins have
been characterized in many pathogens, and some have been dis-
covered in B. burgdorferi, including DbpA, BBK32, P66, Bgp,
BBB07, andBBA33 (21–27, 54).B. burgdorferi has an outer surface
rich in lipoproteins, many of which are hypothesized to interact
with host structures and provide for optimal adhesion and/or im-
mune evasion.
This study was started as part of screening for B. burgdorferi
proteins that could engage host integrins. Despite the linkage of
BB0744, also known as p83/100 (58), as a serodiagnostic marker
forB. burgdorferi infection (40–42), little is known about a role for
this protein in borrelial pathogenesis. Because of its RGD integrin-
binding motif and the ability of BB0744 to bind to 1 integrins
(21), specifically 11 (not shown), we hypothesized that BB0744
may use a leader peptidase I signal sequence to be exported to the
TABLE 2 Oligonucleotides used in this study
Oligonucleotide Sequence (5= to 3=)a Description
P1 GGTACCGAGCTCGGATCCACAAACTCGTTTGGAAGTATAAGCT Primer pair used to amplify 1.5-kb region upstream of
bb0744 with 20-bp 5= flanking region homologous
to insertion site of pCR2.1-TOPO and 3= flanking
region homologous to 5= region of PflgB-aadA
bb0744US-R TTCGCCATTCGGTACCGCGTAAAAGAAATTCTCCTATAAATTTAA
TTATAATCTACC
pflgB-SpecF-KpnI ACGCGGTACCGAATGGCGAATGGCGCGGCC Primer pair used to amplify PflgB-Str
r cassette from
pKFSS1pflgB-SpecR-KpnI ACGCGGTACCCCACGAAGTCCCGGGAGAACCC
bb0744DS-F GACTTCGTGGGGTACCGCGTCTTTACAGTTAGATTTAATTTG
TATAAATCGT
Primer pair used to amplify 1.5-kb region upstream of
bb0744 with 20-bp 5= flanking region homologous
to insertion site of PflgB-aadA and 3= flanking region
homologous to 5= region of pCR2.1-TOPO
P2 CTAGATGCATGCTCGAGCGGATTTCAAAACCAATTGAAACATTGC
744KO seq1 TTTACTTCTTGAAGAGATCCTTAATTC Primers used for sequencing and verification of
fragments and final product of p744KO and
p744Comp prior to transformation into B.
burgdorferi
744KO seq2 CAAAATATCTATAAAGCTTGCCTCTTG
744KOseq3 GTAGGTCGAAAAACGGCAAA
744KOseq4 AAAATTAACAAACTCTTGGAGCAAA
744KOseq5 GACAATATTCATGAAAGTGATTCCA
744KOseq6 TTCTAAAGCTTCTAGCAAAGAAAAA
744KOseq7 CTGCAAATCTTCCAGGCTCT
aadA-F seq CCCGTCATACTTGAAGCTAGACAG
aadA-R seq ATTTGCCGACTACCTCCTTGGTG
bb0744US-744-R CGGCTCTAGCCGAATGCGCATTACTTAACTTTCTTTAAAGTAT
TTACATCTAAA
Primers used in conjunction with P1 and P2,
respectively, to amplify fragments containing 1.5-kb
region upstream of bb0744 and bb0744 and 1.5-kb
region downstream of bb0744 with 20-bp 5= and 3=
flanking regions homologous to PflgB-aacC
aacC-bb0744DS-F TTCGAGCCCATAATGGATCCCTTTACAGTTAGATTTAATAATT
TGTATAAATCGT
flgB-aacC-F CCTAGGTAATACCCGAGCTTCA Primer pair used to amplify PflgB-Gent
r cassette from
pBSV2GflgB-aacC-R ACGCGTAAGCCGATCTCG
b-Actin-F ACGCAGAGGGAAATCGTGCGTGAC Primer pair used for enumeration of copies of mouse
-actin via qPCR (72)b-Actin-R ACGCGGGAGGAAGAGGATGCGGCAGTG
nTM17FrecA GTGGATCTATTGTATTAGATGAGGCT Primer pair used for enumeration of copies of B.
burgdorferi recA via qPCR (38)nTM17RrecA GCCAAAGTTCTGCAACATTAACACCT
5= BB0744 ORF GGATCCAGAGAAGTTGATAGGGAAAAATTAAAGGAC Primer pair used to amplify bb0744 ORF for
recombinant protein expression3= BB0744 ORF GCGGCCGCTATTACTTAACTTTCTTTAAAGTATTTACATC
a Restriction sites are underlined.
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cell envelope and be surface exposed within the outer membrane
of B. burgdorferi. The localization of this protein in outer mem-
brane vesicles provided further evidence that BB0744 might be
surface exposed (43). However, multiple approaches suggested
that, while exported, BB0744 was not surface exposed, despite its
association with outer membrane vesicle preparations during in-
tegrin binding screening (not shown). The localization studies
instead suggested that BB0744 might be anchored to the inner
leaflet of the outer membrane or interact with outer membrane
proteins within the periplasm. Despite the observation that
BB0744 appears to be a periplasmic protein, thus reducing the
possibility that BB0744 interacts directly with host proteins, the
deletion of bb0744 still resulted in a tissue-specific infectivity de-
fect (Table 3; Fig. 4 and 5). As a corollary to this, the inability of the
bb0744 mutant strain to infect heart and distal skin sites implies
that the functional activity associated with BB0744 may be the
consequence of BB0744 envelope proteins that are required for
normal surface protein conformation or lipid structures, particu-
FIG 4 Bioluminescent temporal and spatial tracking of a B. burgdorferi bb0744mutant strain in living mice. BALB/c mice were infected with a dose of 103 (A)
or 105 (B) cells ofML23/pBBE22luc (parent), SH100/pBBE22luc (bb0744), or SH200/pBBE22luc (bb0744 complemented [Comp]).Mice indicated by plus signs
were treated with D-luciferin (D-Luc) at the time points indicated (d, day). Mice indicated by minus signs were not given a substrate and were used to assess the
background. The images obtained are 10-min exposures, and all of the images shown are adjusted to the same scale, as indicated by the color spectrum scale on
the right.
TABLE 3 Infectivity of bb0744 derivative in the ML23/pBBE22luc background
Strain and inoculum dose
(no. of cells)
No. of cultures positive/total
Pinnaa Skinb Lymph node Heart Spleen Bladder Joint All sites
ML23/pBBE22luc (parent)
103 4/4 4/4 4/4 4/4 4/4 4/4 4/4 28/28
105 4/4 3/4 4/4 4/4 4/4 4/4 4/4 27/28
SH100/pBBE22luc (bb0744)
103 0/4 4/4 4/4 0/4 0/4 4/4 4/4 16/28
105 0/4 4/4 4/4 0/4 0/4 4/4 4/4 16/28
SH200/pBBE22luc (bb0744 complemented)
103 4/4 3/4 4/4 4/4 4/4 4/4 4/4 27/28
105 4/4 4/4 4/4 4/4 3/4 4/4 4/4 27/28
a Represents cultivation from a distal skin site, specifically, the ear pinna.
b Represents the site of inoculation on the abdominal skin.
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larly for heart, lymph node, and joint colonization. Further exper-
iments are required to identify the proteins that BB0744 specifi-
cally recognizes.
Infection of BALB/c mice with the ML23 background bb0744
knockout strain (SH100/pBBE22luc) demonstrated a loss of infec-
tivity in the heart, spleen, and ear when cultivation of infected
tissues was the readout independent of the dose (Table 3). Inter-
estingly, the qPCR results demonstrate that even tissues that are
culture positive for SH100/pBBE22luc exhibit a lighter bacterial
load than the parental and/or complemented strain, with the ex-
ception of the site of inoculation where the numbers are not sig-
nificantly different (Fig. 5). One reasonable explanation for the
phenotype observed is a defect in the bb0744 mutant’s ability to
bind to and colonize the host structures found in these tissues.
However, this would not account for themutant’s being unable to
bind cartilage in the ear yet still being able to infect joint cartilage,
unless the ligands are not structures common to both of these
locations. It is important to note that two additional genetic back-
grounds lacking bb0744, specifically, strains B31 5A4NP1 and 297,
exhibited a similar infectivity pattern in which heart tissue and
distal skin sites were not infected (data not shown). These results
indicated that the infectivity defect associated with the loss of
BB0744was not restricted to the B31ML23 background alone and
provide independent validation regarding the phenotype ob-
served.
The combination of the cultivation data and bioluminescent
imaging shows that SH100/pBBE22luc colonizes the joints poste-
rior to the site of B. burgdorferi injection, as well as the regional
(inguinal) lymph nodes (Table 3 and Fig. 4). These data also dem-
onstrate that over the course of 3 weeks, in contrast to the parental
and complemented strains, the SH100/pBBE22luc spirochetes are
unable to move anterior to a point near the midline of the trans-
verse plane of the mouse torso and never gain access to the upper
torso, anterior limbs, or head (Fig. 4). We speculate that this lo-
cation may reflect a limited ability to disseminate for reasons that
are not yet known.
Another alternative for this observed phenotype posits that
replication is delayed (or the survival rate is lower) during infec-
tion and, with slower infection kinetics, the spirochetes are unable
to spread to the mouse anterior. However, this theory loses merit
when infectivity is compared to that of the parental strain. SH100/
pBBE22luc is able to invade the joints in the same time frame as its
parent, ML23/pBBE22luc, yet is still unable to infect the spleen
(Table 3). Wild-type virulent B. burgdorferi infects the spleen be-
fore the joints (13, 61). These data support the idea that either the
kinetics of dissemination are impaired or B. burgdorferi may dis-
seminate to target sites at differential rates, which reduces the
spread of the spirochete to skin sites peripheral to the site of inoc-
ulation. Although this may be the case, particularly for spread
throughout the skin, we cannot exclude the possibility that the
mutant is also impaired for colonization at specific tissues. Assess-
ment of alterations in tissue tropism will require additional vali-
dation but is feasible considering the variability in the tissues that
B. burgdorferi can target during infection and the unique struc-
tures associated with these different tissues.
There are three primary mechanisms that may explain how a
periplasmically localized protein like BB0744 may be required for
the pathogenic potential of B. burgdorferi. (i) BB0744 is part of a
metabolic or stress response pathway that regulates the expression
of various surface proteins. (ii) BB0744 has a role in targeting
surface proteins to the outermembrane or even “flipping” them to
the outer leaflet, e.g., functioning or augmenting the activity of a
membrane “flippase.” (iii) The size of BB0744 suggests that it may
act as a linker between outer and inner membrane proteins. All of
these theories need to be tested in future experiments.
Carditis is a common clinical feature of Lyme disease, with
physical symptoms and medical complications linked to un-
treated infections (7, 12, 66). As SH100/pBBE22luc is unable to
infect the heart during infection, it is possible that BB0744 is
needed indirectly for the stabilization of an important cell enve-
lope structure(s) that provides adhesion to host cells and thus
promotes colonization of the heart and the subsequent develop-
ment of carditis. We are currently exploring these possibilities to
decipher how BB0744 affects these unique pathogenic properties.
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